QWO
Peakcollagenase clostridium histolyticum-aaes
BLASUBCUTANEOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 58m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QWO is a subcutaneous collagenase injection approved in 2020 for cellulite treatment in adults. It works by breaking down collagen in the subcutaneous tissue responsible for the dimpled appearance of cellulite. This is the first and only FDA-approved injectable treatment for this indication.
Peak
Product is in peak commercial phase with moderate competitive pressure; expect stable commercial team focused on market penetration and physician education.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QWO is a peak-stage aesthetic medicine product with strong brand differentiation but modest job market linkage. Roles focus on physician engagement, patient education, and reimbursement strategy in the growing cellulite treatment segment.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.